

1 page

1654

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Sophie Chen

Docket No.

NOV-0001

Serial No.
10/072,8523


Filing Date
February 8, 2002

Examiner
Michael V. Meller

Group Art Unit
1654

Invention:

ANTICANCER AGENTS AND METHOD OF USE THEREOF



I hereby certify that this IDS (1 pg); Trans. of IDS (2 pgs); Inf. Disc. Cit. (8 pgs) & 57 references
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

on April 9, 2004
(Date)

Lindsay Wells

(Typed or Printed Name of Person Mailing Correspondence)

Lindsay Wells

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
NOV-0001

In Re Application Of: SophieChen



Serial No. 10/072,823	Filing Date February 8, 2002	Examiner Michael V. Meller	Group Art Unit 1654
--------------------------	---------------------------------	-------------------------------	------------------------

Title:

ANTI-CANCER AGENTS AND METHOD OF USE THEREOF

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
NOV-0001

In Re Application: SophieChen

APR 12 2004

Serial No.
10/072,823

Filing Date
February 8, 2002

Examiner
Michael V. Meller

Group Art Unit
1654

ANTI-CANCER AGENTS AND METHOD OF USE THEREOF

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 9, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lindsay Wells

Signature of Person Mailing Correspondence

Lindsay Wells

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.

Karen A. LeCuyer
Signature

Dated: April 8, 2004

Karen A. LeCuyer Ph.D.
Registration No. 51,928
Customer No. 23413
Cantor Colburn LLP
55 Griffin Road South
Bloomfield, CT 06002
(860) 286-2929

CC:



NOV-0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sophie Chen)) Group Art Unit: 1654
Serial No.: 10/072,823)) Examiner:
Filing Date: February 8, 2002)) Michael V. Meller
For: ANTI-CANCER AGENTS AND))
METHODS OF USE THEREOF))

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By: Karen A. LeCuyer
Karen A. LeCuyer Ph.D.
Registration No. 51,928

Date: April 8, 2004
Customer No. 23,413
(860) 286-2929



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

(Use several sheets if necessary)

APR 12 2004

卷之三

ATTY DOCKET NO.
NOV-0001

SERIAL NO.

10/072,823

Sophie Chen

FILING

February 8, 2002

GROUP

1654

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	:	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
3	/	WO 01/30342 A1	5/3/2001	PCT			✓	
4	✓	EP 0 742 012 A2	11/13/1996	Europe			✓	
5	/	WO 00/03706	1/27/2000	PCT				✓
6		WO 98/48790	11/5/1998	PCT			✓	
7	✓	EP 0 906 761 A2	7/4/1999	Europe			✓	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

✓	8	Ikemoto Shinichi et al, "Antitumor Effects of Scutellariae radix and its Component Baicalein, Baicalin, and Wogonin on Blader Cander Cell Lines", UROLOGY, Vol. 55, No. 6, June 2000, pages 951-955
✓	9	Lee Woan-Rouh et al, "Wagonin and Fisetin Induce Apoptosis in Human Promyeloleukemic Cells, Accompanied by a Decrease of Reactive Oxygen Species, and Activation of Caspase 3 and Ca ²⁺ - Dependent Endonuclease", BIOCHEMICAL PHARMACOLOGY, Vol. 63, No. 2, 15 January 2002, pages 225-236


EXAMINER

DATE CONSIDERED

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)

APR 12 2004

(Use several sheets if necessary)

(or several sheets if necessary)

ATTY DOCKET NO.
NOV-0001

SERIAL NO.

10/072,823

Sophie Chen

FILING

February 8, 2002

GROUP

1654

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
17 ✓		WO 01/80855 A1	11/1/2001	PCT			✓	
18 ✓		EP 1 159 963 A1	5/12/2001	Europe			✓	
19 ✓		WO 01/68098 A	9/20/2001	PCT			✓	
20 ✓		EP 1 374 880 A	1/2/2004	EUROPE			✓	
21 ✓		WO 02/076484 A	10/3/2002	PCT			✓	


OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

		22 ✓	Ma Jing, et al; "Apoptosis Induced by Isoliquiritigenin in Human Gastric Cancer MGC-803 Cells"; PLANTA MEDICA; Vol. 67, No. 8; November 2001; pages 754-757
		23 ✓	Kubo M, et al; "Scutekkaruaw Raduz 7. Anti-Arthritic and Anti-Inflammatory Actions of Methanolic Extract and Flavonoid Components from Scutellariae Radix", CHEMICAL AND PHARMACEUTICAL BULLETIN (TOKYO); Vol. 32, No. 7; 1984; pages 2724-2729


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 12 2004

ATTY DOCKET NO.
NOV-0001

SERIAL NO.
10/072,823

Sophie Chen

FILING

February 8, 2002

GROUP

1654

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
31 ✓	WO 01/21009 A2	3/29/2001	PCT				✓	
32 ✓	EP 1 029 545 A2	8/23/2000	EUROPE					✓
33 ✓	GB 2 346 325 A	8/9/2000	GREAT BRITAIN				✓	
34 ✓	EP 0 633 022 A	1/11/1995	EUROPE				✓	
35 ✓	EP 1 127 572 A	8/29/2001	EUROPE				✓	


OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

		Naohito, et al; "Resistance of Highly Branched (1-fwdarw 3) - beta-D-glucans to Formolysis"; CHEMICAL AND PHARMACEUTICAL BULLETIN (TOKYO); Vol. 43, No. 6; 1995, Abstract Only; XP 002268301
	36 ✓	Hamuro et al; "Solid Phase Activation of Alternate Pathway of Complement by Beta-1 3 Glucons and its Possible Role for Tumor Regressing Activity"; IMMUNOLOGY, Vol. 34, No. 4; 1978; Abstract Only; XP 002268302

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

APR 12 2004

(Use several sheets if necessary)

(See several sheets if necessary)

ATTY DOCKET NO.
NOV-0001

SERIAL NO.
10/072,823

Sophie Chen

FILING

February 8, 2002

GROUP

1654

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
38 ✓		DE 101 18 999 A	11/8/2001	GERMANY				✓
39 ✓		WO 97/11692	4/3/1997	PCT			✓	
40 ✓		WO 02/076241 A	10/3/2002	PCT			✓	
41 ✓		GB 1 476 016 A	6/10/1977	GREAT BRITAIN			✓	
42 ✓		WO 03/074065 A	9/12/2003	PCT			✓	


OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

		JP 2255622, Abstract Only, 1989-03-28, XP 002268303, 1 page
	43 X	Fukai et al; "Cytotoxic Activity of Low Molecular Weight Polyphenols Against Human Oral Tumor Cell Lines"; ANTICANCER RESEARCH; Vol. 20; 2000; pages 2525-2536

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)


Docket Number (Optional) NOV-0001	Application Number 10/072,823
Applicant(s) Sophie Chen	
Filing Date February 8, 2002	Group Art Unit 1654

*EXAMINER OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

45 ✓	JP 09301915, Abstract Only, 25-11-97, 1 page
46 ✓	Dae Sik Jang et al, "Prenylated Flavonoids of the Leaves of Macaranga Conifera with Inhibitory Activity Against Cyclooxygenase-2", PHYTOCHEMISTRY, Vol. 61, 2002, pages 867-872
47	International Search Report, International Application No. PCT/US 03/06979, International Filing Date 06/03/2002, Date of Mailing 01/03/2004
48	International Search Report, International Application No. PCT/US 03/24088, International Filing Date 01/08/2003, Date of Mailing 05/03/2004
49 ✓	JP 60178815, Abstract Only, 1986-01-29, XP002268305 1 page
50 ✓	JP 06024975, Abstract Only, 1994-02-01, XP002268306, 1 page
51 ✓	JP 61263925, Abstract Only, 1986-11-21, XP 002268307, 1 page
52 ✓	JP 08104628, Abstract Only, 1996-04-23. XP 002268308, 2 pages
53 ✓	JP 2000 239136, Abstract Only, 2000-09-05, XP 002268309, 2 pages
54 ✓	JP 04283518, Abstract Only, 1992-10-08, XP 002268310, 1 page
55 ✓	JP 2001 114675, Abstract Only, 2001-05-24, XP 002268311, 4 pages
56 ✓	JP 52 145509, Abstract Only, 1977-12-03, XP 002268312, 1 page

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.